Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company’s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which is in Phase III clinical trial for the treatment of moderate-to-severe plaque psoriasis; DRM04, a small-molecule anticholinergic product that has completed a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage progra...
275 Middlefield Road
Menlo Park, CA 94025
Founded in 2010
Dermira, Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015
May 12 15
Dermira, Inc. reported consolidated earnings results for the first quarter ended March 31, 2015. For the quarter ended March 31, 2015, Dermira reported net loss of $14.0 million or $0.57 per basic and diluted share, compared with net loss of $8.5 million or $9.56 per basic and diluted share for the same period in 2014. Loss from operations was $14.2 million against $8.5 million a year ago.
Dermira, Inc. to Report Q1, 2015 Results on May 11, 2015
May 11 15
Dermira, Inc. announced that they will report Q1, 2015 results After-Market on May 11, 2015
Dermira, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015
Mar 25 15
Dermira, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, loss from operations was $6,782,000 against $6,692,000 last year. Net loss was $6,727,000 compared to $6,714,000 a year ago. Net loss per basic and diluted share was $0.29 against $7.56 last year. Revenue for the quarter ended December 31, 2014 was $7.3 million.
For the year ended, loss from operations was $31,698,000 against $22,303,000 last year. Net loss was $31,875,000 compared to net loss of $22,350,000 last year. Net loss per basic and diluted share was $4.96 against $27.03 last year. Revenue for the year ended December 31, 2014 was $7.3 million.
For the year 2015, the company expects non-GAAP operating expenses for 2015, excluding the impact of stock-based compensation expense, to be in the range of $80 million to $85 million and to have approximately $90 million in cash and cash equivalents and investments as of year-end 2015.